

# RESPONDER-HF Trial

## Patient Identification Tip Card



Atrial shunt therapy for HF patients with EF  $\geq 40\%$

### KEY PATIENT CHARACTERISTICS

- Age  $\geq 40$  years old
- NYHA Class II, III, or ambulatory IV HF with:
  - $\geq 1$  HF hospitalization, IV or  $\uparrow$  oral diuretics (past 12m); OR
  - Normal or modestly elevated BNP / NT-proBNP (past 6m)
- Ongoing stable HF GDMT & comorbidity management
- Echocardiographic evidence of diastolic dysfunction
- BMI  $< 45 \text{ kg/m}^2$

### **NO current/history of the following:**

- Implanted pacemaker, ICD, or CRT
- Hemodynamically significant valve disease ( $\geq 3+$  MR,  $>$ mild MS, grade  $\geq 2+$  TR,  $\geq 2+$  AR,  $>$ moderate AS)
- Stroke, TIA, DVT or PE (past 6m)
- RV dysfunction  $>$ mild or TAPSE  $< 1.4 \text{ cm}$
- On dialysis or eGFR  $< 25 \text{ ml/min/1.73 m}^2$

*NOTE: Invasive hemodynamic evaluation required to determine trial eligibility*

**For more information please contact:**

# COMMON SIGNS THAT EXERTIONAL DYPNIA IS DUE TO HFpEF



Resting PCWP, LVEDP, or LAP > 15 mmHg



Chart notes include: “shortness of breath”, “heart failure”, “fluid overload”, “diuresis”, “edema”



LA enlargement  
Septum bowing into RA  
LV hypertrophy



H<sub>2</sub>FPEF Score of **3+**  
(see below)

## H<sub>2</sub>FPEF SCORING MODEL<sup>1</sup>

Sum points to identify HFpEF among patients with exertional dyspnea.

| Clinical Variable                    | Values                                 | Points    |
|--------------------------------------|--|-----------|
| <b>H<sub>2</sub></b> Heavy           | Body mass index > 30 kg/m <sup>2</sup> | <b>+2</b> |
| <b>H<sub>2</sub></b> Hypertensive    | On > 2 anti-hypertensives              | <b>+1</b> |
| <b>F</b> Atrial <b>F</b> ibrillation | Paroxysmal or Persistent AF            | <b>+3</b> |
| <b>P</b> Pulmonary Hypertension      | RVSP > 35 mmHg                         | <b>+1</b> |
| <b>E</b> Elder                       | Age > 60 years                         | <b>+1</b> |
| <b>F</b> Filling Pressure            | E/e' > 9                               | <b>+1</b> |

| A score of                       | 3    | 4    | 5    | 6+   |
|----------------------------------|------|------|------|------|
| Indicates a HFpEF probability of | >50% | >70% | >80% | >90% |



Corvia Medical, Inc.

One Highwood Drive, Suite 300  
Tewksbury, MA 01876 USA

1. Reddy YNV, et al. *Circulation*. 2018;138(9):861-870.

Study sponsored by Corvia Medical. clinicaltrials.gov  
identification #NCT05425459

IASD and Corvia are registered trademarks of Corvia Medical, Inc.

©2022 Corvia Medical, Inc.

All rights reserved. PS00734, 00731AW Rev 00 2022-10